FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2005431539> ?p ?o ?g. }

• W2005431539 endingPage "13" @default.
• W2005431539 startingPage "7" @default.
• W2005431539 abstract "To review the contemporary management of symptomatic benign prostatic hyperplasia (BPH) in North America.Information was obtained from published scientific articles, lay press articles, Medicare outcomes data, IMS market analysis data and surveys among primary care practitioners and urologists.A survey in Olmsted County in the US identified the number of men with an I-PSS score >7 and maximum urinary flow rate <15 ml/s. This survey found that 17% of men in the 50-59 year old age bracket, 27% of men in the 60-69 bracket and 37% of men in the 70-79 bracket meet this minimum criterion for discussions about treatment. Currently in the US, there are approximately 5.6 million men that fall in this category, and the number is expected to double by the year 2025. Primary care physicians in 25% of cases and internal medicine in 24% of cases provide initial management of BPH. Urologists provide initial management in 37% of cases. Improvement in urinary symptoms and quality of life is the most important health outcome in the management of symptomatic BPH in the US, particularly because serious complications from BPH are distinctly uncommon. A survey among urologists determined that for men with mild symptoms, watchful waiting was employed 77% of the time, alpha(1)-adrenoceptor antagonists 21% and finasteride 1%. For those with moderate symptoms and prostate volume </=40 ml, alpha(1)-adrenoceptor antagonists are employed 88% of the time, finasteride 1% and TURP 1%. When the prostate is in excess of 40 ml, alpha(1)-adrenoceptor antagonists are used 69% of the time, finasteride 10% and TURP 9%. alpha(1)-Adrenoceptor antagonists are also employed most of the time for patients with severe symptoms: 58% of the time for small and 45% of the time for large prostates. The respective data for TURP are 31% and 38%. Primary care physicians utilize predominantly watchful waiting and long-acting alpha(1)-adrenoceptor antagonists. Laser use in the management of BPH has fallen from 40% of urologists in 1994 to 26% in 1997. TUMT and TUNA are each employed by 3% of urologists. The use of transurethral vaporisation of the prostate has increased to 62% of urologists. For those patients being treated with medication, 36% are treated with terazosin, 31% with doxazosin, 15% with finasteride and 18% with tamsulosin, which was introduced only recently and is growing.In the future, the number of older men in the US will increase dramatically. Likely the percentage of patients undergoing surgical treatment such as TURP will decrease but the absolute number having surgery will increase. It is also likely that alpha(1)-adrenoceptor antagonists will be used with greater frequency in the future and finasteride will be used less frequently. Copyrightz1999S.KargerAG,Basel" @default.
• W2005431539 created "2016-06-24" @default.
• W2005431539 creator A5087921119 @default.
• W2005431539 date "1999-01-01" @default.
• W2005431539 modified "2023-10-16" @default.
• W2005431539 title "Management of Symptomatic BPH in the US: Who Is Treated and How?" @default.
• W2005431539 cites W100997517 @default.
• W2005431539 cites W1972848666 @default.
• W2005431539 cites W2025633679 @default.
• W2005431539 cites W2034949435 @default.
• W2005431539 cites W2049518269 @default.
• W2005431539 cites W2077488673 @default.
• W2005431539 cites W2079080443 @default.
• W2005431539 cites W2088509391 @default.
• W2005431539 cites W2088697451 @default.
• W2005431539 cites W2090839011 @default.
• W2005431539 cites W2117494881 @default.
• W2005431539 cites W2162595546 @default.
• W2005431539 cites W2415491170 @default.
• W2005431539 cites W2577042876 @default.
• W2005431539 cites W2993539218 @default.
• W2005431539 doi "https://doi.org/10.1159/000052343" @default.
• W2005431539 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/10559625" @default.
• W2005431539 hasPublicationYear "1999" @default.
• W2005431539 type Work @default.
• W2005431539 sameAs 2005431539 @default.
• W2005431539 citedByCount "77" @default.
• W2005431539 countsByYear W20054315392013 @default.
• W2005431539 countsByYear W20054315392014 @default.
• W2005431539 countsByYear W20054315392015 @default.
• W2005431539 countsByYear W20054315392016 @default.
• W2005431539 countsByYear W20054315392018 @default.
• W2005431539 countsByYear W20054315392019 @default.
• W2005431539 countsByYear W20054315392021 @default.
• W2005431539 crossrefType "journal-article" @default.
• W2005431539 hasAuthorship W2005431539A5087921119 @default.
• W2005431539 hasConcept C121608353 @default.
• W2005431539 hasConcept C126322002 @default.
• W2005431539 hasConcept C126894567 @default.
• W2005431539 hasConcept C141071460 @default.
• W2005431539 hasConcept C159110408 @default.
• W2005431539 hasConcept C2775874879 @default.
• W2005431539 hasConcept C2776141087 @default.
• W2005431539 hasConcept C2776235491 @default.
• W2005431539 hasConcept C2777562237 @default.
• W2005431539 hasConcept C2779951463 @default.
• W2005431539 hasConcept C2780192828 @default.
• W2005431539 hasConcept C2780542891 @default.
• W2005431539 hasConcept C2780904754 @default.
• W2005431539 hasConcept C29456083 @default.
• W2005431539 hasConcept C71924100 @default.
• W2005431539 hasConceptScore W2005431539C121608353 @default.
• W2005431539 hasConceptScore W2005431539C126322002 @default.
• W2005431539 hasConceptScore W2005431539C126894567 @default.
• W2005431539 hasConceptScore W2005431539C141071460 @default.
• W2005431539 hasConceptScore W2005431539C159110408 @default.
• W2005431539 hasConceptScore W2005431539C2775874879 @default.
• W2005431539 hasConceptScore W2005431539C2776141087 @default.
• W2005431539 hasConceptScore W2005431539C2776235491 @default.
• W2005431539 hasConceptScore W2005431539C2777562237 @default.
• W2005431539 hasConceptScore W2005431539C2779951463 @default.
• W2005431539 hasConceptScore W2005431539C2780192828 @default.
• W2005431539 hasConceptScore W2005431539C2780542891 @default.
• W2005431539 hasConceptScore W2005431539C2780904754 @default.
• W2005431539 hasConceptScore W2005431539C29456083 @default.
• W2005431539 hasConceptScore W2005431539C71924100 @default.
• W2005431539 hasIssue "Suppl. 3" @default.
• W2005431539 hasLocation W20054315391 @default.
• W2005431539 hasLocation W20054315392 @default.
• W2005431539 hasOpenAccess W2005431539 @default.
• W2005431539 hasPrimaryLocation W20054315391 @default.
• W2005431539 hasRelatedWork W1681900410 @default.
• W2005431539 hasRelatedWork W2266492914 @default.
• W2005431539 hasRelatedWork W2365076467 @default.
• W2005431539 hasRelatedWork W2366419473 @default.
• W2005431539 hasRelatedWork W2372985415 @default.
• W2005431539 hasRelatedWork W2389954374 @default.
• W2005431539 hasRelatedWork W2397598598 @default.
• W2005431539 hasRelatedWork W2530014601 @default.
• W2005431539 hasRelatedWork W4237663250 @default.
• W2005431539 hasRelatedWork W2259762283 @default.
• W2005431539 hasVolume "36" @default.
• W2005431539 isParatext "false" @default.
• W2005431539 isRetracted "false" @default.
• W2005431539 magId "2005431539" @default.
• W2005431539 workType "article" @default.